Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study (vol 24, 229, 2023)

被引：0
|
作者：
Ismaila, Afisi S. [1 ,2 ]
Rothnie, Kieran J. [3 ]
Wood, Robert P. [4 ]
Banks, Victoria L. [4 ,5 ]
Camidge, Lucinda J. [4 ]
Czira, Alexandrosz [3 ]
Compton, Chris [6 ]
Sharma, Raj [6 ]
Millard, Shannon N. [4 ,7 ]
Massey, Olivia [4 ]
Halpin, David M. G. [8 ]
机构：
[1] GSK, R&D Global Med, Value Evidence & Outcomes, 1250 South Collegeville Rd, Collegeville, PA 19426 USA
[2] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[3] GSK, Value Evidence & Outcomes, R&D Global Med, London, England
[4] Adelphi Real World, Real World Evidence, Bollington, England
[5] Bayer PLC, Integrated Evidence Generat Womens Hlth Care, Reading, England
[6] GSK, Global Med, London, England
[7] P1vital Ltd, Wallingford, Oxon, England
[8] Univ Exeter, Med Sch, Coll Med & Hlth, Exeter, England
来源：
RESPIRATORY RESEARCH | 2024年 / 25卷 / 01期
关键词：
D O I：
10.1186/s12931-024-02745-x
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 22 条
  • [1] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Ismaila, Afisi S.
    Rothnie, Kieran J.
    Wood, Robert P.
    Banks, Victoria L.
    Camidge, Lucinda J.
    Czira, Alexandrosz
    Compton, Chris
    Sharma, Raj
    Millard, Shannon N.
    Massey, Olivia
    Halpin, David M. G.
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [2] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Afisi S. Ismaila
    Kieran J. Rothnie
    Robert P. Wood
    Victoria L. Banks
    Lucinda J. Camidge
    Alexandrosz Czira
    Chris Compton
    Raj Sharma
    Shannon N. Millard
    Olivia Massey
    David M. G. Halpin
    Respiratory Research, 24
  • [3] Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Afisi S. Ismaila
    Kieran J. Rothnie
    Robert P. Wood
    Victoria L. Banks
    Lucinda J. Camidge
    Alexandrosz Czira
    Chris Compton
    Raj Sharma
    Shannon N. Millard
    Olivia Massey
    David M. G. Halpin
    Respiratory Research, 25
  • [4] Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
    Mannino, David
    Bogart, Michael
    Germain, Guillaume
    Huang, Shirley P.
    Ismaila, Afisi S.
    Laliberte, Francois
    Jung, Young
    MacKnight, Sean D.
    Stiegler, Marjorie A.
    Duh, Mei Sheng
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 491 - 504
  • [5] Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
    Sandeep Bansal
    Martin Anderson
    Antonio Anzueto
    Nicola Brown
    Chris Compton
    Thomas C. Corbridge
    David Erb
    Catherine Harvey
    Morrys C. Kaisermann
    Mitchell Kaye
    David A. Lipson
    Neil Martin
    Chang-Qing Zhu
    Alberto Papi
    npj Primary Care Respiratory Medicine, 31
  • [6] Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
    Bansal, Sandeep
    Anderson, Martin
    Anzueto, Antonio
    Brown, Nicola
    Compton, Chris
    Corbridge, Thomas C.
    Erb, David
    Harvey, Catherine
    Kaisermann, Morrys C.
    Kaye, Mitchell
    Lipson, David A.
    Martin, Neil
    Zhu, Chang-Qing
    Papi, Alberto
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2021, 31 (01)
  • [7] Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
    Meredith McCormack
    Rosirene Paczkowski
    Noelle N. Gronroos
    Stephen G. Noorduyn
    Lydia Lee
    Phani Veeranki
    Mary G. Johnson
    Emmeline Igboekwe
    Kristin Kahle-Wrobleski
    Reynold Panettieri
    Advances in Therapy, 2024, 41 : 1245 - 1261
  • [8] Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
    Mccormack, Meredith
    Paczkowski, Rosirene
    Gronroos, Noelle N.
    Noorduyn, Stephen G.
    Lee, Lydia
    Veeranki, Phani
    Johnson, Mary G.
    Igboekwe, Emmeline
    Kahle-Wrobleski, Kristin
    Panettieri, Reynold
    ADVANCES IN THERAPY, 2024, 41 (03) : 1245 - 1261
  • [9] Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study
    Pavord, Ian
    Peachey, Guy
    Kerstjens, Huib
    Kerwin, Edward
    Nathan, Robert
    Hanania, Nicola
    Pascoe, Steven
    Fowler, Andrew
    Bailes, Zelie
    Edwards, Dawn
    Sule, Neal
    Barnes, Neil
    Boulet, Louis-Philippe
    Tabberer, Maggie
    Lee, Laurie
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB241 - AB241
  • [10] Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study
    Pavord, Ian
    Peachey, Guy
    Kerstjens, Huib
    Kerwin, Edward
    Nathan, Robert
    Hanania, Nicola A.
    Pascoe, Steven
    Fowler, Andrew
    Bailes, Zelie
    Edwards, Dawn
    Sule, Neal
    Barnes, Neil
    Boulet, Louis-Philippe
    Tabberer, Maggie
    Lee, Laurie A.
    ALLERGY AND ASTHMA PROCEEDINGS, 2020, 41 (06) : 459 - 460
123